Skip to main content

Hamilton Global Opportunities plc (ALHGO.PA) announces the initiation of coverage of its shares by Euroland Corporate

Hamilton Global Opportunities plc (ALHGO.PA) announces the initiation of coverage of its shares by Euroland Corporate London, United Kingdom 23 April 2026, 7:30 GMT – Hamilton Global Opportunities plc (“HGO”) today announces the initiation of coverage of its shares by EuroLand Corporate. This initiative reflects HGO’s ambition to strengthen its visibility within the financial community and enhance its profile among investors, both in France and internationally. This first research report, titled “The harvest begins”, was published by EuroLand Corporate on April 23, 2026. It includes a Buy recommendation and a target price of €50.40 per share. The release of this research note also comes at a symbolic moment for HGO, as it coincides with the fifth anniversary of the Company’s IPO. The report is available on Boursorama, as well as on the...

Continue reading

Michelin: Disclosure of trading in own shares – April 23rd, 2026

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND Information about securities repurchasing programRegulated informationIssuer social denomination: Michelin – LEI 549300SOSI58J6VIW052 Types of securities: ordinary shares – Code ISIN FR001400AJ45Date : April 23rd, 2026Issuer Name Issuer code Transactiondate ISIN Code Daily total volume (in number of actions) Daily weighted average price of shares acquired PlatformCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 23.04.2026 FR001400AJ45 220 090 29.7356 euros Over-the-counterCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 23.04.2026 FR001400AJ45 220 090 29.7356 euros Over-the-counterCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 23.04.2026 FR001400AJ45 220 090 29.7356 euros Over-the-counterIssuer Name Issuer...

Continue reading

AS Tallink Grupp Unaudited Consolidated Interim Report for the Q1 2026

The results of AS Tallink Grupp for the Q1 2026 will be introduced at an Investor Webinar held today at 12:00 (EEST). To participate, please join via the following link; we kindly ask participants to provide their questions latest by 11:00 am by email to: investor@tallink.ee. Further details are available in a previously published announcement. In the first quarter 2026, AS Tallink Grupp and its subsidiaries (the Group) carried 1,036,405 passengers, representing a 6.8% increase year-on-year. The number of cargo units transported increased by 13.4% to 65,578 while the number of passenger vehicles was up by 1.2% to 137,479. The Group’s unaudited consolidated revenue amounted to EUR 149.4 million compared to EUR 137.3 million in the first quarter 2025. Unaudited EBITDA totalled EUR 2.1 million (negative EBITDA of EUR 3.8 million in the first...

Continue reading

AS-i Tallink Grupp 2026. majandusaasta auditeerimata konsolideeritud I kv tulemuste vahearuanne

The results of AS Tallink Grupp for the Q1 2026 will be introduced at an Investor Webinar held today at 12:00 (EEST). To participate, please join via the following link; we kindly ask participants to provide their questions latest by 11:00 am by email to: investor@tallink.ee. Further details are available in a previously published announcement. In the first quarter 2026, AS Tallink Grupp and its subsidiaries (the Group) carried 1,036,405 passengers, representing a 6.8% increase year-on-year. The number of cargo units transported increased by 13.4% to 65,578 while the number of passenger vehicles was up by 1.2% to 137,479. The Group’s unaudited consolidated revenue amounted to EUR 149.4 million compared to EUR 137.3 million in the first quarter 2025. Unaudited EBITDA totalled EUR 2.1 million (negative EBITDA of EUR 3.8 million in the first...

Continue reading

Liquidity Provider Agreement with ABG Sundal Collier ASA

Gabriel Holding A/S has entered a market maker agreement with ABG Sundal Collier ASA effective 24 April 2026. The purpose of the Liquidity Provider scheme is to create liquidity on Nasdaq Copenhagen in the listed share and can be summarized as follows:ABG Sundal Collier ASA commits to continuously facilitate trading in the Gabriel Holding A/S shares by quoting prices, within a range considered acceptable, on either the buy or sell side in the market. ABG Sundal Collier ASA’s quotation is made without Gabriel Holding A/S’ interference Purchases/sales are at ABG Sundal Collier ASA’s expense and riskThe Liquidity Provider Agreement will remain in force until terminated by either Gabriel Holding A/S or ABG Sundal Collier ASA. The agreement has been concluded with reference to prevailing minimum requirements for liquidity...

Continue reading

BE Semiconductor Industries N.V. Announces Q1-26 Results

Q1-26 Orders of € 269.7 Million Up 104.5% vs. Q1-25 Revenue of € 184.9 Million and Net Income of € 51.6 Million Up 28.3% and 63.8%, Respectively, vs. Q1-25 DUIVEN, the Netherlands, April 23, 2026 (GLOBE NEWSWIRE) — BE Semiconductor Industries N.V. (the “Company” or “Besi”) (Euronext Amsterdam: BESI; OTC markets: BESIY), a leading manufacturer of assembly equipment for the semiconductor industry, today announced its results for the first quarter ended March 31, 2026. Key HighlightsRevenue of € 184.9 million was up 11.1% vs. Q4-25 and 28.3% vs. Q1-25 due primarily to higher shipments for high-end mobile and 2.5D AI computing applications Orders of € 269.7 million were up 7.7% vs. Q4-25 primarily due to a significant increase in bookings for hybrid bonding systems. Vs. Q1-25, orders grew 104.5% due to broad based...

Continue reading

74Software completes refinancing of its Term Loans and Revolving Credit Facility

Press Release 74Software completes refinancing of its Term Loans and Revolving Credit Facility Paris, April 23, 2026 – 74Software announces the completion of the refinancing of its syndicated bank facilities. The transaction refinances the Group’s existing bank indebtedness, comprising a €120 million revolving credit facility maturing in 2027, an €80 million Term Loan B maturing in 2027, and a €120 million amortizing Term Loan A maturing in 2029. These facilities have been refinanced through:a new €180 million revolving credit facility, maturing in 2031, with two extension options; and a new €230 million amortizing term loan, maturing in 2031.The refinancing was executed with the Group’s existing banking pool and the participation of a new relationship bank. Following the transaction, the average maturity of 74Software’s financial...

Continue reading

NORBIT ASA – Annual Report for 2025

Trondheim, 23 April 2026: NORBIT today announces that it has published its Annual Report for 2025, which also includes the sustainability reporting in accordance with CSRD and the Corporate Governance Report, which the board of directors approved on 22 April 2026.  “2025 became another record year for NORBIT. We delivered record revenues and strengthened profitability, while further reinforcing our market positions across segments. The results reflect consistent execution, strong demand, and the dedication of a capable and committed organisation”, says Per Jørgen Weisethaunet, CEO of NORBIT. The report is attached to this notice and is also available at the company’s website, www.norbit.com, under Investors. The company also publishes its annual financial statements in European Single Electronic Format (ESEF), available as...

Continue reading

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

Nantes, France, April 23, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi® in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, United States (May 29 – June 2, 2026). Alexandra Leary, MD, PhD, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), oncologist specialising in gynaecological cancers, Chair of the GINECO group and Lead Investigator of the TEDOVA Phase 2 clinical trial of Tedopi®, will present...

Continue reading

Interim report: January – March 2026

First quarterOrder intake increased by 19% to SEK 1,108 m (930). Organically, order intake increased by 10% Net sales increased by 9% to SEK 971 m (890. Organically, net sales increased by 15% EBITA reached SEK 264 m (205), equal to a 27.2% (23.1) margin EBIT reached SEK 237 m (175), equal to a 24.4% (19.6) operating margin Profit after tax totaled SEK 163 m (115) and basic earnings per share were SEK 3.24 (2.29) Profit after tax adjusted for amortization of excess values from acquisitions (adjusted profit after tax) totaled SEK 190 m (146) and adjusted basic earnings per share were SEK 3.78 (2.91) Cash flow from operating activities amounted to SEK 250 m (187) Acquisition of Molex’s industrial communications businessLast twelve monthsOrder intake increased by 11% to SEK 3,633 m (3,269). Organically, order intake increased by 10% Net...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.